Mast cell tumor medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 51: Line 51:
*Malabsorption
*Malabsorption
|}
|}


====Antihistamines====
====Antihistamines====

Revision as of 21:30, 2 March 2016

Mast cell tumor Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mast Cell Tumor from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Diagnostic criteria

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT Scan

MRI

Biopsy

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mast cell tumor medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mast cell tumor medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mast cell tumor medical therapy

CDC on Mast cell tumor medical therapy

Mast cell tumor medical therapy in the news

Blogs on Mast cell tumor medical therapy

Directions to Hospitals Treating Mast cell tumor

Risk calculators and risk factors for Mast cell tumor medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical Therapy

The treatment of mast cell tumor is mainly focused on avoidance of triggering factors (e.g. physical stimuli such as heat or cold, alcohol, drugs such as aspirin and other NSAIDS) and symptomatic therapy. Commonly used medications for symptomatic relief include:[1]

Medication Indications

H1 antihistamine

  • Pruritus
  • Flushing
  • Anaphylaxis

H2 antihistamine

  • Pruritus
  • Anaphylaxis
  • Diarrhea
  • Nausea
  • Vomiting
  • Abdominal discomfort

Mast cell stabilizers

  • Abdominal cramping
  • Malabsorption

Proton pump inhibitors

  • Peptic ulcers

Epinephrine

  • Anaphylaxis

Steroids

  • Anaphylaxis
  • Malabsorption

Antihistamines

  • Antihistamines block receptors targeted by histamine released from mast cells. Both H1 and H2 blockers may be helpful.
  • Leukotriene antagonists block receptors targeted by leukotrienes released from mast cells.
  • Antihistamines frequently treat itching and other skin complaints.
  • Certain antihistamines work specifically against ulcers

Mast cell stabilizers

  • Mast cell stabilizers help prevent mast cells from releasing their chemical contents.
  • Cromolyn sodium oral solution (Gastrocrom® / Cromoglicate) is the only medicine specifically approved by the U.S. FDA for the treatment of mastocytosis.
  • Ketotifen is available in Canada and Europe, but is only available in the U.S. as ophthalmic drops (Zaditor®).
  • Cromolyn sodium may help reduce cramping in the abdomen.

Proton pump inhibitors

  • Proton pump inhibitors help reduce production of gastric acid, which is often increased in patients with mastocytosis.
  • Excess gastric acid can harm the stomach, esophagus, and small intestine.

Epinephrine

  • Epinephrine constricts blood vessels and opens airways to maintain adequate circulation and ventilation when excessive mast cell degranulation has caused anaphylaxis.
  • Epinephrine treats symptom flares which occur with shock, referred to as "anaphylaxis".

Albuterol

  • Albuterol and other beta-2 agonists open airways that can constrict in the presence of histamine.

Steroid

  • Corticosteroids can be used topically, inhaled, or systemically to reduce inflammation associated with mastocytosis.
  • Steroids treat malabsorption or impaired ability to take in nutrients.

Antidepressants

  • Antidepressants are an important and often overlooked tool in the treatment of mastocytosis.
  • The stress and physical discomfort of any chronic disease may increase the likelihood of a patient developing depression.
  • Depression and other neurological symptoms have been noted in mastocytosis.[2] Some antidepressants such as doxepin are themselves potent antihistamines and can help relieve physical as well as cognitive symptoms.

Calcium channel blocker

A 1984 study by Fairly et al. included a patient with symptomatic urticaria pigmentosa who responded to nifedipine at dose of 10 mg po tid.[3] However, Nifedipine has never been approved by the FDA for treatment of mastocytosis. In aggressive forms of systemic mastocytosis, treatments such as interferon alpha, cladribin, and imatinib mesylate should to be considered. Imatinib seems to be more effective in patients without the D816V C-kit mutation.

Chemotherapy

  • In rare cases in which mastocytosis is cancerous or associated with a blood disorder, the patient may have to use steroids and/or chemotherapy.
  • The novel agent imatinib (Glivec® or Gleevec®) has been found to be effective in certain types of mastocytosis.[4]
  • Recent literature shows that C-Kit (D816V) lends some resistance to imatinib and sorafenib but these cells are still sensitive to nilotinib, dasatinib and rapamycin. Cladribine and interferon have also been found to be effective.


References

  1. Koenig, Martial; Morel, Jérôme; Reynaud, Jacqueline; Varvat, Cécile; Cathébras, Pascal (2008). "An unusual cause of spontaneous bleeding in the intensive care unit – mastocytosis: a case report". Cases Journal. 1 (1): 100. doi:10.1186/1757-1626-1-100. ISSN 1757-1626.
  2. Rogers MP, Bloomingdale K, Murawski BJ, Soter NA, Reich P, Austen KF. Mixed organic brain syndrome as a manifestation of systemic mastocytosis. Psychosom Med 1986;48:437-47. PMID 3749421
  3. Fairley JA, et al: Urticaria pigmentosa responsive to nifedipine. J Am Acad Dermatol 11:740-743, 1984.
  4. Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006 Jul 15;107(2):345-51. PMID 16779792

Template:WH Template:WS